Menu

Report Library

All Reports

HR +/ HER2 - Breast Cancer KOL Interview - UK #2

November 20, 2026

A UK- based oncologist shares perspectives on HR+/HER2- breast cancer epidemiology, in-depth insights into the treatment landscape for various settings and lines of therapy, patient progression, and the promising emerging therapies/regimens. The interview highlights for HR+/HER2- breast cancer in the UK, practice follows local guidelines aligned with ESMO but is constrained by NICE funding.

This interview was conducted on August 19, 2026. 

 

If you are a Datamonitor Healthcare client, you may access the interview from our KOL Insight channel.

If you are a KOL Insight subscriber, you may also access the interview from our KOL Insight portal.

Biomedtracker’s KOL Insight transcripts are available through subscription only. For more information on obtaining a KOL Insight subscription, please email Biomedtracker or call Biomedtracker Client Services at (888) 670-8900. 

For our disclosures, please read the Biomedtracker Research Standards.

Indications Covered: HR+/HER2- Breast Cancer